Background {#Sec1}
==========

Pulmonary arterial hypertension (PAH) is a progressive disease associated with increased pulmonary vasculature resistance, increased pulmonary arterial pressure, and right heart failure \[[@CR1]\]. The clinical diagnosis of pulmonary arterial hypertension (PAH) is defined by a mean pulmonary arterial pressure ≥ 25 mmHg at rest and pulmonary capillary wedge pressure ≤ 15 mmHg by right heart catheterization \[[@CR2]\]. Although the mechanisms leading to PAH are still unclear, endothelial apoptosis is widely considered to be an initiating process that reduces the effective lung vasculature area through functional pulmonary microvascular rarefaction and obliterative remodeling of the small pulmonary arterioles due to the emergence of growth dysregulated vascular cells and endothelial cell dropout \[[@CR3]\]. Ultimately, loss of lung microcirculation leads to progressive increases in pulmonary vascular resistance, right ventricular remodeling, and eventually right heart failure \[[@CR2], [@CR4], [@CR5]\].

Regenerative cell therapy has emerged as a novel treatment for PAH that has been examined in many preclinical animal studies and applied in several clinical trials \[[@CR6], [@CR7]\]. The majority of preclinical models report the use of two main cell types: early-outgrowth endothelial progenitor cells (EPCs, also known as circulating angiogenic cells, myeloid angiogenic cells) and mesenchymal stromal cells (MSCs, also known as mesenchymal stem cells, adult stem cells) \[[@CR6], [@CR8]\]. EPCs and MSCs have demonstrated the ability to migrate to sites of vascular injury in several in vivo animal disease models \[[@CR9]\] secreting paracrine factors which induce vascular repair and reduce inflammation \[[@CR6]\]. Preclinical studies involving EPCs and MSCs have demonstrated efficacy by reducing pulmonary pressures, regenerating lost microvascular area, and reducing both pulmonary vascular and right ventricular remodeling \[[@CR6]\]. Three small clinical trials (2 adult, 1 pediatric) involving regenerative cell therapy on PAH patients have been completed and demonstrate some promise in limiting disease burden \[[@CR7], [@CR10], [@CR11]\]. However, to date, there has been no systematic synthesis of preclinical studies investigating stem cell therapy for the treatment of PAH. A synthesis of this preclinical data may identify knowledge gaps, impact the design of further preclinical testing of cell therapies, and potentially influence the design of future clinical trials.

In this systematic review and meta-analysis, we quantified the effects of regenerative cell therapy on pulmonary hemodynamics based on currently available data in preclinical studies. Cells from all sources were considered, as well as all enhancements (e.g., gene transfected). We also provide a comprehensive review of study methodology, assessment of bias, and publication bias.

Methods/design {#Sec2}
==============

Protocol and registration {#Sec3}
-------------------------

Our protocol was published \[[@CR12]\] and also posted on the Collaborative Approach to Meta Analyses and Review of Animal Data from Experimental Studies (CAMRADES) website (<http://syrf.org.uk>). Reporting of this review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Additional file [1](#MOESM1){ref-type="media"}) \[[@CR13]\].

Eligibility criteria {#Sec4}
--------------------

We included interventional studies (randomized, pseudo-randomized, and non-randomized) that examined an in vivo model of experimentally induced PAH comparing the effect of regenerative cell administration versus a diseased control. Both unmodified cells and enhanced cells (e.g., gene transfected) were considered. Valid preclinical in vivo models of PAH that reproduced features of the pathophysiology associated and/or etiology of human PAH \[[@CR1]\] were the rodent monocrotaline (MCT) and SU5416 + chronic hypoxia (SU+CH) models. Prevention and treatment type studies were included. Mouse models were excluded in this systematic review as available models at the time of data extraction (chronic hypoxia) lacked significantly elevated pulmonary pressures, right ventricular hypertrophy, and pulmonary arteriolar remodeling \[[@CR14]\]. Animal models of PAH secondary to other causes such as left heart disease, lung disease, or thromboembolism (WHO groups 3--5) \[[@CR2]\] were excluded. Genetically modified animals and neonatal animal models were also excluded.

Outcomes were assessed at least 1 week after intervention to exclude the possibility of acute effects of cell administration. Our primary outcomes were measures of pulmonary hemodynamics (mean pulmonary arterial pressure, right ventricular systolic pressure). Secondary outcomes included survival and right ventricular (RV) remodeling expressed as the weight ratio of right ventricle/left ventricle + septum (RV/LV+S).

Literature search {#Sec5}
-----------------

We searched Ovid MEDLINE®, Ovid MEDLINE® In-Process & Other Non-Indexed Citations, and EMBASE Classic+ until January 2018. The search strategy was developed by an information specialist and validated using the Peer Review of Electronic Search Strategies (PRESS) by another information specialist (Additional file [2](#MOESM2){ref-type="media"}) \[[@CR15]\]. The search used combination of controlled vocabulary (for example stem cells, pulmonary hypertension), and keywords (for example EPC, MSC, iPSC, HSC, PAH) and parsing were formatted accordingly to each database. In addition, we performed a manual review of the bibliographies of selected articles and relevant reviews. Only articles in the English language were included in the review.

Study selection process {#Sec6}
-----------------------

Citations from the literature search were collated, and duplicate studies removed. Titles and abstracts of search results were screened independently by two reviewers (CW, BL, NW, CS) using DistillerSR software (Evidence Partners, Ottawa, ON). Abstracts deemed potentially relevant were recorded, and full-text articles obtained. Remaining articles moved forward for full-text review, which was also performed in duplicate (CW, BL, NW, CS). Disagreements between reviewers were resolved by consensus or by a third-party consultation (DJS or MML). The study selection process was documented and reported using a PRISMA flow diagram (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR13]\].Fig. 1PRISMA flow diagram

Data extraction and risk of bias assessment {#Sec7}
-------------------------------------------

Data was extracted independently by two individuals into standardized, electronic pilot-tested forms. Data was collected on general study characteristics (e.g., study design, funding source, and origin), on regenerative cell characteristics (cell type, dose, enhancements, etc.), and on primary and secondary outcomes. Disagreements during extraction were resolved by consensus or third-party consultation (MML or DJS). In the case of missing or unclear data for the primary or secondary outcome measures, an attempt was made to contact the primary study author(s) for clarification. Risk of bias was assessed independently in duplicate for each included study using the SYRCLE (Systematic Review Centre for Laboratory animal Experimentation) risk of bias tool \[[@CR16]\], and each parameter for the type of bias was scored as low, high, or unclear risk of bias.

Data analysis {#Sec8}
-------------

Studies were pooled using Comprehensive Meta-Analyst (v3; Biostat Inc., USA). For continuous endpoints, mean difference (MD) or standardized mean difference (SMD) was calculated, depending on the measurement of the outcome. MD and SMD were calculated using random effects of inverse variance meta-analyses and presented with accompanying 95% confidence intervals. For dichotomous outcomes, risk ratios were calculated using a random effects analysis based on the Der-Simonian Laird model and presented with accompanying 95% confidence intervals. Statistical heterogeneity of included studies was measured using the *I*^*2*^ statistic \[[@CR17]\]. An *I*^*2*^ value of \> 50% was determined to indicate important heterogeneity worth further exploration. We assessed the potential for publication bias using funnel plots and Egger's regression test \[[@CR18]\].

A priori defined subgroup analyses were examined on the primary endpoint of right heart catheterization hemodynamics (RVSP/mPAP). The pre-planned subgroups that were analyzed included regenerative cell type, cell enhancement (cell pretreatments/priming, gene transfection), and timing of administration. For timing of cell therapy, interventions administered prior to 14 days were considered "early" based on the rat monocrotaline model (where hemodynamic changes are not noted prior to this timepoint after disease induction) \[[@CR14]\]. A post hoc subgroup analysis was performed examing the effect of cell compatibility (i.e., allogeneic and xenogeneic) on the primary endpoint of right heart catheterization hemodynamics (RVSP/mPAP). In addition, we performed post hoc subgroup analysis exploring the effect of cell dose and cell origin (bone marrow, umbilical, adipose) on studies which administered MSCs.

Results {#Sec9}
=======

Study characteristics {#Sec10}
---------------------

Our systematic search yielded a total of 1285 articles. After preliminary screening, 94 articles were identified for full-text review, of which 45 studies met eligibility criteria for this review (Fig. [1](#Fig1){ref-type="fig"}). Baseline characteristics are reported in Table [1](#Tab1){ref-type="table"}. Studies were published between 2003 and 2017, with 14 studies from China, 8 studies from the USA, 6 studies from Korea, 6 studies from Japan, 5 from Taiwan, 2 from Canada, and 1 each from Netherlands, Brazil, Egypt, and Italy. Sample size ranged from 7 to 51, and follow-up duration ranged from 7 to 173 days. The majority of the studies were conducted in rats (43 out of 45), with 2 studies in dogs \[[@CR19], [@CR20]\].Table 1Summary of study characteristics of included studiesAnimal model characteristicsCell characteristicsReferenceCountrySpecies (strain)Intervention (days)Follow-up (days)Stem cell typeCell species of originTissue of origin for cell productTransplant typeDoseRouteCell enhancementNagaya 2003 \[[@CR32]\]JapanRat (nude athymic)714EPCHumanUmbilical cord bloodXenogenic1,000,000IV (intrajugular)Adrenomedullin transfectionTakahashi 2004 \[[@CR19]\]JapanDog (beagle)1428EPCDogPeripheral bloodAutologous1,000,000IV (intrajugular)Zhao 2005a \[[@CR33]\]CanadaRat (Fischer)2114EPCRatBone marrowAllogeneic1,000,000IV (intrajugular)eNOSZhao 2005b \[[@CR33]\]CanadaRat (Fischer)321EPCRatBone marrowAllogeneic1,500,000IV (intrajugular)Kanki-Horimoto 2006 \[[@CR34]\]JapanRat (Sprague Dawley)714MSCRatBone marrowAllogeneic1,000,000IV (intrajugular)Baber 2007 \[[@CR35]\]USARat (Sprague Dawley)1435MSCRatBone marrowAllogeneic3,000,000IntratrachealSpees 2008USARat (Sprague Dawley)2121BM-MNCRatBone marrowAllogeneic5,000,000IV (tail vein)Yip 2008a \[[@CR36]\]TaiwanRat (Sprague Dawley)783EPCRatBone marrowAutologous1,200,000IV (tail vein)Yip 2008b \[[@CR36]\]TaiwanRat (Sprague Dawley)721EPCRatBone marrowAutologous1,200,000IV (tail vein)Sun 2009a \[[@CR37]\]TaiwanRat (Sprague Dawley)342EPCRatBone marrowAutologous2,000,000IV (tail vein)Cilostazol pretreatmentSun 2009b \[[@CR37]\]TaiwanRat (Sprague Dawley)342EPCRatBone marrowAutologous2,000,000IV (tail vein)Umar 2009 \[[@CR38]\]NetherlandsRat (Wistar)1414MSCRatBone marrowAllogeneic1,000,000IV (intrajugular)Ormiston 2010 \[[@CR22]\]CanadaRat (nude athymic)321EPC (early and late)HumanPeripheral bloodXenogenic1,500,000IV (intrajugular)Takemiya 2010 \[[@CR39]\]JapanRat (Lewis)1428MSCRatBone marrowAllogeneic500,000IV (tail vein)PCS transfectionAngelini 2011 \[[@CR40]\]ItalyRat (Sprague Dawley)287MSCRatAdiposeAllogeneic4,000,000IV (tail vein)Mirsky 2011a \[[@CR41]\]USARat (nude athymic)3510 and 15EPCHumanPeripheral bloodXenogenic1,500,000IV (tail vein)Mirsky 2011b \[[@CR41]\]USARat (nude athymic)3510 and 15EPCHumanPeripheral bloodXenogenic1,500,000IV (tail vein)Jiang 2012 \[[@CR42]\]ChinaRat (Sprague Dawley)318MSCBone marrowAllogeneic4,000,000IV (tail vein)Kim 2012 \[[@CR43]\]KoreaRat (Sprague Dawley)728BM-MNCRatBone marrowAllogeneic20,000,000IV (tail vein)Luan 2012 \[[@CR30]\]ChinaRat (Sprague Dawley)2114MSCRatBone marrowAllogeneic100,000IV (right femoral vein)Luan 2012 \[[@CR20]\]ChinaDog (Mongrel)1456BM-MNCDogBone marrowAllogeneic1,300,000IntratrachealSun 2012 \[[@CR44]\]TaiwanRat (Sprague Dawley)335EPCRatBone marrowAutologous2,000,000IV (tail vein)Xie 2012 \[[@CR45]\]ChinaRat (Sprague Dawley)714MSCRatBone marrowAllogeneic1,000,000IV (right femoral vein)Yen 2013 \[[@CR46]\]TaiwanRat (Sprague Dawley)2169EPCRatBone marrowAutologous2,000,000IV (penile vein)Zhou 2013a \[[@CR47]\]USARat (Fischer)325EPCRatBone marrowAllogeneic1,500,000IV (intrajugular)COX1-PCS transfectionZhou 2013b \[[@CR47]\]USARat (Fischer)2128EPCRatBone marrowAllogeneic1,500,000IV (intrajugular)COX1-PCS transfectionChen 2014 \[[@CR48]\]ChinaRat (Sprague Dawley)2114MSCRatBone marrowAllogeneic1,000,000IV (tail vein)Eguchi 2014 \[[@CR49]\]JapanRat (Wistar)721MSCRatAdiposeAllogeneic7,000,000IV (tail vein)Guo 2014 \[[@CR50]\]ChinaRat (Sprague Dawley)2121MSCRatBone marrowAllogeneic5,000,000IV (intrajugular)Luan 2014 \[[@CR51]\]ChinaRat (Sprague Dawley)7173MSCRatBone marrowAllogeneic10,000,000IV (sublingual vein)Somanna 2014 \[[@CR52]\]USARat (Sprague Dawley)1414MSCRatAdiposeAllogeneic3,000,000IntratrachealCOX1 transfectionIkutomi 2015a \[[@CR53]\]JapanRat (Fischer)0, 1, 3, 5, 7, 919EPC-earlyRatBone marrowAllogeneic1 × 10^6^ per injection (total 6×)IV (tail vein)Ikutomi 2015b \[[@CR53]\]JapanRat (Fischer)0, 1, 3, 5, 7, 919EPC-lateRatBone marrowAllogeneic1 × 10^6^ per injection (total 6×)IV (tail vein)Ikutomi 2015c \[[@CR53]\]JapanRat (Fischer)0, 1, 3, 5, 7, 919EPC-very lateRatBone marrowAllogeneic1 × 10^6^ per injection (total 6×)IV (tail vein)Kang 2015 \[[@CR54]\]KoreaRat (Lewis)1414MSCHumanUmbilical cord bloodAllogeneic250,000IV (tail vein)S1p primingLee 2015 \[[@CR55]\]KoreaRat (Sprague Dawley)77MSCHumanUmbilical cord bloodXenogenic3,000,000IV (intrajugular)Liang 2015 \[[@CR56]\]ChinaRat (Sprague Dawley)7 or 147MSCRatAdiposeAllogeneic1,000,000IV (intrajugular)Liu 2015 \[[@CR57]\]ChinaRat (Sprague Dawley)516MSCHumanUmbilical cord bloodXenogenic1,000,000IV (tail vein)Luo 2015 \[[@CR58]\]ChinaRat (Sprague Dawley)147MSCRatAdiposeAllogeneic1,000,000IV (intrajugular)Pan 2015 \[[@CR59]\]ChinaRat (Sprague Dawley)7, 14, 217,14,21EPCRatBone marrowAllogeneic1,000,000IV (tail vein)shRNA-CD40 transfectionChen 2016a \[[@CR60]\]ChinaRat (Wistar)1421MSCRatBone marrowAllogeneic1,000,000IV (tail vein)eNOS/F92A-Cav1Chen 2016b \[[@CR60]\]ChinaRat (Wistar)1421MSCRatBone marrowAllogeneic1,000,000IV (tail vein)F92A-Cav1Chen 2016c \[[@CR60]\]ChinaRat (Wistar)1421MSCRatBone marrowAllogeneic1,000,000IV (tail vein)eNOSHuang 2016 \[[@CR61]\]TaiwanRat (Sprague Dawley)0 or 1414iPSCMouseNot reportedXenogenic2,000,000IV (tail vein)None (compared to conditioned media)Kim 2016 \[[@CR62]\]KoreaRat (Sprague Dawley)77 and 21MSCHumanUmbilical cord bloodXenogenic3 × 10^6^/ml/cm^2^IV (intrajugular)Lim 2016 \[[@CR63]\]KoreaRat (Lewis)1414MSCHumanBone marrowXenogenic250,000IV (tail vein)C1P (ceramide-1 phosphate) primingRathinasabapathy 2016 \[[@CR64]\]USARat (Sprague Dawley)1414MSCRatAdiposeAllogeneic1,000,000IPVarshney 2016 \[[@CR65]\]USARat (Sprague Dawley)318MSCmouseNot reportedXenogenic3,500,000IV (intrajugular)GFP-SKL (secreted Klotho) transfectionAhmed 2017 \[[@CR66]\]EgyptRat (Wistar)1414EPCRatBone marrowAllogeneic1,000,000IV (no specific site indicated)pinocembrin preconditioningCheng 2017 \[[@CR67]\]ChinaRat (Lewis)2121MSCRatBone marrowAllogeneic3,000,000IV (tail vein)Let7a transfectionde Mendonca 2017 \[[@CR68]\]BrazilRat (Wistar)1421MSCRatAdiposeAllogeneic100,000IV (intrajugular)Lee 2017 \[[@CR69]\]KoreaRat (Sprague Dawley)1, 714 and 28MSCHumanUmbilical cord bloodXenogenic3,000,000, 1,000,000, 300,000IV (intrajugular) (multiple doses and timing)Middleton 2017 \[[@CR70]\]USARat (Sprague Dawley)1421CDCRatHeartAllogeneic2,000,000IV (intrajugular)Luo 2018 \[[@CR71]\]ChinaRat (Sprague Dawley)1421MSCRatAdiposeAllogeneic1,000,000IV (intrajugular)Adiponectin transfectionLetters following the author and year (ex. Chen 2016a) indicate that more than one experiment or treatment was conducted in the same publication

Studied cell types included bone marrow mononuclear cell (BM-MNC) (*n* = 3), cardiosphere-derived cells (CDC) (*n* = 1), endothelial progenitor cell (EPC) (*n* = 13), induced pluripotent stem cell (iPSC) (*n* = 1), and mesenchymal stem cell (MSC) (*n* = 27). Forty-one studies (91%) administered the cells intravenously, three studies (7%) administered the cells intratracheally, and one study (2%) administered the cell intra-peritoneally. The cell dose used ranged from 100,000 total cells to 20 million total cells. The timing of cell administration ranged from immediately following PAH induction to 35 days post-PAH induction. Seventeen studies used cell enhancement strategies, and 28 studies did not. All studies used a fresh cell product.

Primary outcomes {#Sec11}
----------------

### Right ventricular systolic pressure (RVSP) {#Sec12}

Twenty-six studies reported data on RVSP from 44 experiments (805 animals). Cell therapy was associated with a significant reduction in RVSP compared to control (SMD − 2.10; 95% CI − 2.59 to − 1.60) (Fig. [2](#Fig2){ref-type="fig"}a). In a post hoc analysis using weighted mean difference (WMD), animals which had received regenerative cell therapy saw a 13.7-mmHg reduction in RVSP (95% CI − 16.2 to − 11.1) (Additional file [3](#MOESM3){ref-type="media"}: Figure S1).Fig. 2Forest plot of effect of regenerative cell therapy on RVSP in preclinical models of PAH (**a**). Reported in standardized mean difference and 95% confidence intervals. Subgroup analysis of RVSP and **b** cell enhancement, **c** cell type, and **d** timing of administration. Letters indicate two separate experiments within the same publication. Asterisk denotes cell enhancement within the same experiment, right single quotation mark indicates different cell subtype within the same experiment, and subscript number denotes a separate study/publication within the same year

The treatment effect was analyzed by pre-defined subgroups (cell type, cell enhancement, and timing of treatment, species). Cell enhancement by gene transfection or small molecule pretreatment/priming was associated with a greater reduction in RVSP compared to non-enhanced cells (Fig. [2](#Fig2){ref-type="fig"}b) (*p* = 0.001). Subgroup analysis by cell type showed significant reductions in RVSP for all cell types, with the exception of bone marrow mononuclear cells (Fig. [2](#Fig2){ref-type="fig"}c). For bone marrow mononuclear cells (BM-MNC) and cardiosphere-derived cells (CDC) cell types, only one study was available to contribute data to each. Post hoc analysis demonstrated that MSCs had a significantly greater effect in lowering RVSP than EPCs (*p* \< 0.001). Cell therapy administered at 14 days or later was associated with a greater reduction in RVSP compared to cell therapy administered less than 14 post disease induction (Fig. [2](#Fig2){ref-type="fig"}d). In a post hoc subgroup analysis of cell compatibility, there was no difference in effect between allogeneic, autologous, or xenogeneic cell therapy (Additional file [3](#MOESM3){ref-type="media"}: Figure S2).

Visual inspection of the funnel plot indicated potential publication bias, which was supported by Egger's regression (*p* \< 0.001). Post hoc trim and fill analysis suggests a 45% overestimation of effect. Accounting for potential publication bias, cell therapy remained associated with a significant reduction in RVSP (SMD − 1.45; 95% CI − 1.98 to − 0.92) (Additional file [3](#MOESM3){ref-type="media"}: Figure S3). In post hoc analyses of MSC studies only, there was no difference in effect between high vs low dose, or MSC source (Additional file [3](#MOESM3){ref-type="media"}: Figures S4-S5).

Mean pulmonary arterial pressure (mPAP) {#Sec13}
---------------------------------------

Eleven studies (16 experiments) reported data on mPAP (16 experiments, 233 animals). Overall, regenerative cell therapy was associated with a significant reduction in mPAP compared to control (SMD − 2.16; 95% CI − 2.97 to − 1.35) (Fig. [3](#Fig3){ref-type="fig"}a). There was no difference in effect between enhanced and non-enhanced cells, although data from enhanced cell studies was sparse (*n* = 3) (Fig. [3](#Fig3){ref-type="fig"}b). Subgroup analysis by cell type showed significant reductions in mPAP for treatment with EPC and MSC; however, post hoc analysis demonstrated no significant benefit of one cell type over the other (Fig. [3](#Fig3){ref-type="fig"}c). Subgroup analysis by timing of treatment suggests efficacy when cell therapy was administered at less than 21 days (Fig. [3](#Fig3){ref-type="fig"}d). In a post hoc subgroup analysis of cell compatibility, there was no difference in effect between allogeneic, autologous, or xenogeneic cell therapy (Additional file [3](#MOESM3){ref-type="media"}: Figure S6).Fig. 3Forest plot of mean pulmonary arterial pressure in preclinical models of PAH. **a** mPAP for all studies. Subgroup analysis of mPAP by **b** enhancement, **c** cell type, and **d** timing of intervention. Reported in standardized mean difference and 95% confidence intervals. IV intravenous, IT intratracheal. Letters indicate two separate experiments within the same publication. Asterisk denotes cell enhancement within the same experiment

Visual inspection of the funnel plot indicated potential publication bias, which was confirmed by Egger's regression (*p* \< 0.001) (Additional file [3](#MOESM3){ref-type="media"}: Figure S7). Post hoc trim and fill analysis suggests a 5% overestimation of effect. Accounting for potential publication bias, cell therapy remained associated with a significant reduction in mPAP (SMD − 2.05; 95% CI − 2.90 to − 1.21) (Additional file [3](#MOESM3){ref-type="media"}: Figure S7). In post hoc analyses of MSC studies only, there was no difference in effect between different MSC sources; however, a larger effect was observed with a low dose of cells (\< 1 million cells) (Additional file [3](#MOESM3){ref-type="media"}: Figures S8-S9).

Secondary outcomes {#Sec14}
------------------

Twenty-nine studies (50 experiments) reported RV/LV+S from 930 animals. Regenerative cell therapy was associated with an overall decrease in RV remodeling measured by RV/LV+S (SMD − 1.31, 95% CI − 1.64 to − 0.97) (Fig. [4](#Fig4){ref-type="fig"}). Three studies reported data on mortality (87 animals). No statistically significant difference in mortality was observed between groups (RR 2.11, 95% CI 0.12 to 36.04) (Additional file [3](#MOESM3){ref-type="media"}: Figure S10).Fig. 4Forest plot of Fulton's index (RV/LV+S ratio). Reported in standardized mean difference and 95% confidence intervals. Letters indicate two separate experiments within the same publication

Risk of bias (SYRCLE tool) {#Sec15}
--------------------------

Most studies were rated for unclear risk of bias across all categories (Fig. [5](#Fig5){ref-type="fig"}), reflecting incomplete reporting of methodological details. Twenty-two studies (49%) described randomizing animals to treatment and control groups. Two studies (4%) reported blinding the experimenters, while seven studies (16%) reported blinding of outcome assessment. The risk of bias was unclear for all studies across the domains of allocation concealment, baseline characteristic description, random animal housing, random outcome assessment, incomplete outcome data, and selective reporting of outcomes.Fig. 5Risk of bias assessment using the SYRCLE tool

Discussion {#Sec16}
==========

Our systematic review is the first to examine the effect of regenerative cell therapy in preclinical models of PAH. Overall, the results of our meta-analysis demonstrate an improvement in the primary outcome hemodynamics (RVSP, mPAP) and the secondary outcome RV remodeling (RV/LV+S) with regenerative cell therapy. Subgroup analysis showed that the reduction in RVSP was observed in MSC, EPC, and iPSC cell types. Additional subgroup analysis on timing of treatment showed that regenerative cell therapy administered at 3, 7, 14, and 21 days post-induction resulted in significant reductions in RVSP. Efficacy was still observed when treatment was administered beyond 14 days post-induction during established PAH, which represents a clinically meaningful timepoint for intervention.

Several studies included in this meta-analysis examined the utility of cell enhancement strategies such as gene transfection or pharmacological preconditioning. Overall, cell enhancement was associated with greater reduction in RVSP and mPAP compared to treatment with non-enhanced cells. A caveat with this interpretation is that there is potential for publication bias, as ineffective enhancement strategies are less likely to be pursued and published. As well, due to the limited number of studies for each enhancement strategy, we could not compare between gene candidates or preconditioning.

All 45 studies were performed in the MCT model of PAH, and all performed in a male population of rats (*n* = 43 studies) or dogs (*n* = 2 studies) and therefore, the generalizability of these findings may be limited. The MCT model has been criticized for its off-target systemic toxicity to the liver, heart, and kidneys, which also limits the long-term study of treatments in preclinical studies. In recent years, the SU5416 + chronic hypoxia model of PAH has been considered the most representative model of human PAH due to its ability to closely replicate the salient histopathological features of PAH in humans and the profound changes in pulmonary hemodynamics \[[@CR14], [@CR21]\]. Ideally, confirmatory studies in both models would improve validity; however, our systematic search did not identify any studies involving regenerative cell therapy in the SU5416 + chronic hypoxia model.

One of the limitations of this study is that we did not assess histopathological data such as pulmonary vascular remodeling or cell engraftment. Regenerative cell therapy has been proposed to alter pulmonary vascular remodeling, perhaps by reducing endothelial apoptosis and limiting smooth muscle hyperplasia, and could therefore be a useful surrogate outcome to assess efficacy \[[@CR8]\]. However, the lack of consensus scoring systems for assessing pulmonary vascular remodeling in vivo limited our ability to include this in the analysis. Indeed, metrics such as wall thickening, medial hypertrophy, and so forth have been reported, but the scoring criteria were often vague, subjective, and non standardized. As well, cell retention or engraftment in the pulmonary vasculature would support the vascular remodeling hypothesis of cell therapy. Similarly, we found that engraftment was measured by several methods including immunofluorescence staining, transfection with fluorescent tag, or PCR. Within the same study, different techniques (e.g., immunofluorescence vs PCR) yielded variable cell retention rates \[[@CR22]\], likely due to differences in sensitivity and specificity for each technique.

Another limitation of this analysis is that functional outcome measurements were not available. In clinical trials, the 6-min walk test is widely used, \[[@CR23]\]; however, no such standardized functional assessment exists for animal studies. Instead, other surrogate measures of RV function may be available. Indeed, RV function is arguably the most important predictor of prognosis in PAH \[[@CR24]\]. However, accurate quantification of RV ejection fraction in small animals due to the unique and variable geometry of the RV is challenging \[[@CR14], [@CR23]\]. RV dysfunction precedes mortality, and therefore, assessment of RV function could be a useful tool for clinical translation. Tricuspid annular planar systolic excursion (TAPSE) and RV fractional area change are 2D echocardiography measures that were rarely reported in preclinical studies \[[@CR23], [@CR25]\] and thus not included in the meta-analysis. Future studies examining the effect of regenerative cell therapy on cardiac output (CO), cardiac index, or other indices of RV function may provide further insight into the long-term effects of cell therapy. Reporting of important outcomes such as cardiac output and pulmonary vascular resistance (PVR) was almost non-existent in included studies, and therefore, the effect of regenerative cell therapy on these outcomes could not be assessed.

Overall, the studies included in this systematic review were scored as having an unclear or high risk of bias using the itemized SYRCLE Risk of Bias tool for preclinical studies. For instance, although most studies randomize treatment, further measures to minimize bias such as allocation concealment or method of randomization were not reported. This information is critical, as inadequate generation or concealment of allocation is associated with exaggerated effect sizes \[[@CR26]\]. Similarly, lack of blinding of outcome assessment, in which study investigators are unaware of the intervention allocation, is also associated with overestimation of effect size \[[@CR27]\]. Only eight of the included studies reported blinding of outcome assessment. The lack of reporting of key potential sources of bias is consistent with preclinical literature in general. Although several preclinical reporting guidelines have been proposed to enhance transparency and methodological quality in preclinical studies \[[@CR28]\], uptake by authors and journals has not been widespread. This lack of transparency contributes to poor reproducibility from preclinical to clinical trials, which is already strained as only \< 5% of basic science discoveries are eventually approved by health authorities \[[@CR29]\]. The identification of poor methodological reporting, as well as a lack of reporting of important outcomes such as CO and PVR, has identified a knowledge gap and represents a potential next step for future studies in the field.

In conclusion, regenerative cell therapy is associated with improved pulmonary hemodynamics and RV remodeling across several subgroups. The strengths of this study include the large number of studies \[[@CR30]\], comprehensive data collection on model and treatment methodology, and subgroup analysis by cell enhancement, cell type, and timing, which can be used to inform future preclinical studies and clinical trials. The timing of this review is highly relevant, as small clinical trials have been completed (NCT00257413, NCT00641836, NCT00469027) \[[@CR10], [@CR11], [@CR31]\]. So far, based on limited short-term data, the results of completed clinical trials have shown relatively modest benefits \[[@CR10]\] compared to the effect sizes reported in some preclinical literature \[[@CR32], [@CR33]\]. The effect sizes in our review may be influenced in part by potential sources of bias, which may be improved by increased methodological rigor which include randomization, allocation concealment, and blinding in future studies. Alternatively, the difference in effect size could be contributed by the relative homogeneity of animal models of PAH, for example the rodent monocrotaline model, compared to clinical presentations of PAH. Future studies to address the validity of preclinical studies should also include the use of more comprehensive assessments of cardiac function, particularly the RV functional capacity, as well as follow-up confirmatory studies in multiple animal models such as the SU5416 + hypoxia model \[[@CR27]\]. Several variations in regenerative cell therapy methods were evaluated for heterogeneity such as cell type, enhancement, and timing of administration. However, at this time, limited data and lack of head-to-head comparisons preclude the suggestion of an optimal method of cell therapy.
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